Caricamento...
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
Trametinib, a selective inhibitor of mitogen‐activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression‐free survival compared with chemotherapy in patients with BRAF V600E/K mutation–positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permit...
Salvato in:
| Pubblicato in: | Cancer Med |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864810/ https://ncbi.nlm.nih.gov/pubmed/27172483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.643 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|